Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Family Medicine | Geriatrics | Internal Medicine | Nursing | Pharmacy | Conference News

Back to Journal Articles

AHA: Peri-Op Omega-3s Don’t Reduce Atrial Fibrillation

Last Updated: November 07, 2012.

 

No reduction in the risk of a-fib for patients receiving peri-cardiac-op fish oil versus placebo

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Perioperative supplementation with long chain n-3-polyunsaturated fatty acids does not reduce postoperative atrial fibrillation or flutter, compared with placebo, according to a study published online Nov. 5 in the Journal of the American Medical Association to coincide with presentation at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.

WEDNESDAY, Nov. 7 (HealthDay News) -- Perioperative supplementation with long chain n-3-polyunsaturated fatty acids (n-3-PUFAs) does not reduce postoperative atrial fibrillation or flutter (AF), compared with placebo, according to a study published online Nov. 5 in the Journal of the American Medical Association to coincide with presentation at the American Heart Association's Scientific Sessions 2012, held from Nov. 3 to 7 in Los Angeles.

Dariush Mozaffarian, M.D., Dr.P.H., from the Harvard School of Public Health in Boston, and colleagues analyzed data from 1,516 patients scheduled for cardiac surgery in 28 centers in the United States, Italy, and Argentina. Patients participating in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation trial were randomized to receive fish oil (1-g capsules containing at least 840 mg n-3-PUFAs as ethyl esters) or placebo, with loading of 10 g over three to five days preoperatively followed by 2 g/day postoperatively until hospital discharge or postoperative day 10.

The researchers found that postoperative AF lasting longer than 30 seconds occurred in 30.7 percent of patients assigned to placebo and 30.0 percent assigned to n-3-PUFAs (odds ratio, 0.96; P = 0.74). There were no significant differences between the placebo and fish oil groups for any measures of AF, hospital utilization, bleeding, 30-day mortality, or major adverse cardiovascular events.

"In this large multinational trial among patients undergoing cardiac surgery, perioperative supplementation with n-3-PUFAs, compared with placebo, did not reduce the risk of postoperative AF," the authors write.

The study was supported by GlaxoSmithKline, Sigma Tau, and Pronova BioPharma, which also provided the study drug.

Abstract
Full Text
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Vitamin D Levels May Be Linked to Familial Longevity Next: 18% of Patients Who Smoke Light Up While Hospitalized

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.